Jump to content

MMDA-2

From Wikipedia, the free encyclopedia
MMDA-2
Clinical data
Routes of
administration
Oral,Insufflated,Rectal
ATC code
  • none
Legal status
Legal status
Identifiers
  • 1-(6-Methoxy-1,3-benzodioxol-5-yl)propan-2-amine
CAS Number
PubChemCID
ChemSpider
UNII
CompTox Dashboard(EPA)
Chemical and physical data
FormulaC11H15NO3
Molar mass209.245g·mol−1
3D model (JSmol)
  • O1c2cc(c(OC)cc2OC1)CC(N)C

MMDA-2(2-methoxy-4,5-methylenedioxyamphetamine) is apsychedelicdrugof theamphetamineclass.[1]It is closely related toMMDAandMDA.[1]

Alexander Shulginwas likely the first tosynthesizeMMDA-2.[1]In his bookPiHKAL,the dose is listed as 25–50 mg, and the duration is listed as 8–12 hours.[1]Shulgin reports that MMDA-2 produces effects such as enhancedawareness,empathy,andvisual facilitationanddistortion,as well as someside effectslikegastrointestinal upsetandappetite loss.[1]He states that 30 mg is very similar to 80 mg of MDA, and also remarks that it would be impossible for anyone to have a bad experience on the drug at that dose.[1]

Scientific research has shown that MMDA-2, unlike MMDA, but similarly to6-methyl-MDA,is only very weak at inducing the release ofserotoninordopamine,[2]and accordingly, does not produceamphetamine-like responses in animals in drug discrimination studies.[3]Instead, MMDA-2 is likely to act as a pure5-HT2receptoragonistsimilarly to theDOxseries of compounds, with activation of the5-HT2Areceptorconferring its psychedelic effects.[4]

MMDA-2 has been sold as adesigner druginJapan.[5]

See also

[edit]

References

[edit]
  1. ^abcdefShulgin A, Shulgin A (13 May 2016)."MMDA-2 (2-Methoxy-4,5-methylenedioxyamphetamine)".Pihkal: A Chemical Love Story.Transform Press.ISBN978-0-9630096-0-9.
  2. ^McKenna DJ, Guan XM, Shulgin AT (March 1991)."3,4-Methylenedioxyamphetamine (MDA) analogues exhibit differential effects on synaptosomal release of 3H-dopamine and 3H-5-hydroxytryptamine".Pharmacology, Biochemistry, and Behavior.38(3): 505–512.doi:10.1016/0091-3057(91)90005-M.PMID1829838.S2CID2740262.
  3. ^Glennon RA, Yousif M, Naiman N, Kalix P (March 1987). "Methcathinone: a new and potent amphetamine-like agent".Pharmacology, Biochemistry, and Behavior.26(3): 547–551.doi:10.1016/0091-3057(87)90164-X.PMID3575369.S2CID5890314.
  4. ^Clare BW (2002). "QSAR of benzene derivatives: comparison of classical descriptors, quantum theoretic parameters and flip regression, exemplified by phenylalkylamine hallucinogens".Journal of Computer-Aided Molecular Design.16(8–9): 611–633.Bibcode:2002JCAMD..16..611C.doi:10.1023/A:1021966231380.PMID12602954.S2CID9948738.
  5. ^Min JZ, Shimizu Y, Toyo'oka T, Inagaki S, Kikura-Hanajiri R, Goda Y (October 2008). "Simultaneous determination of 11 designated hallucinogenic phenethylamines by ultra-fast liquid chromatography with fluorescence detection".Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences.873(2): 187–194.doi:10.1016/j.jchromb.2008.08.020.PMID18789774.
[edit]